Medical comms - Articles
Pharma bigwigs confirm to speak in India’s biggest event in pharma:
More than 40 Industry leaders will chart the course ahead for the Indian Pharmaceutical and allied Industries
Bangalore will be adding one more feather to its cap. It will soon be playing to host another national event of high importance “The Pharmaceutical Leadership Summit 2009”, to be held at the Hotel Le Meredien on January 24th. The one day summit is being organized with a view to bring together leaders from the industry and crystallize their views and thoughts and assist the industry to find solutions and strategies to help the Indian pharma industry face challenges adroitly and seize opportunities as they arise. The who’s who of pharma industry led by Bangalore’s own Kiran Mazumdar of Biocon Lid, Kewal Handa of…
Bangalore will be adding one more feather to its cap. It will soon be playing to host another national event of high importance “The Pharmaceutical Leadership Summit 2009”, to be held at the Hotel Le Meredien on January 24th. The one day summit is being organized with a view to bring together leaders from the industry and crystallize their views and thoughts and assist the industry to find solutions and strategies to help the Indian pharma industry face challenges adroitly and seize opportunities as they arise. The who’s who of pharma industry led by Bangalore’s own Kiran Mazumdar of Biocon Lid, Kewal Handa of…
With more than 20,000 students, Kingston University is the largest provider of higher education in South West London, offering an extensive range of undergraduate and postgraduate programmes both in the United Kingdom and overseas. The University is renowned for teaching excellence, has established itself as a growing force in research and is widely respected as a pioneer in e-learning.
The first batch of students to complete Kingston University’s new Masters in Pharmacy has picked up their degrees. The awards, which were handed out in a special ceremony at Kingston’s Rose Theatre, marked a major milestone for the University’s School of Pharmacy and Chemistry which launched the MPharm four years ago. Thirty-six students graduated, with five scoring first class honours, and 24 gaining upper…
The first batch of students to complete Kingston University’s new Masters in Pharmacy has picked up their degrees. The awards, which were handed out in a special ceremony at Kingston’s Rose Theatre, marked a major milestone for the University’s School of Pharmacy and Chemistry which launched the MPharm four years ago. Thirty-six students graduated, with five scoring first class honours, and 24 gaining upper…
27-Aug-2010
This feature has been provided by Jonathan Hart-Smith, Managing Director of CK Clinical Limited.
The feature contains useful information for rapport buliding.
If you form a bond with people, and they feel an affinity with you, you will have stronger, more effective and enjoyable relationships. Even if your interaction is brief, whether it be dealing with a customer, a colleague or even attending a job interview you can get more out of the situation if you feel a shared purpose. I hope this article will serve to outline some basic techniques for forming a rapport quickly. Some people say that rapport is formed in the first minute and a half. We are all familiar with the expression “first impressions count” and like it or not, it’s true. When you meet somebody face to face or talk to th…
If you form a bond with people, and they feel an affinity with you, you will have stronger, more effective and enjoyable relationships. Even if your interaction is brief, whether it be dealing with a customer, a colleague or even attending a job interview you can get more out of the situation if you feel a shared purpose. I hope this article will serve to outline some basic techniques for forming a rapport quickly. Some people say that rapport is formed in the first minute and a half. We are all familiar with the expression “first impressions count” and like it or not, it’s true. When you meet somebody face to face or talk to th…
27-Aug-2010
This feature has been provided by Jonathan Hart-Smith,
Managing Director of CK Clinical Limited.
The feature contains useful information for Hiring Managers.
Imagine setting off on a journey. If you don’t know where you are going you will never get there. Before you read a CV for an applicant you need to consider how this role fits into your team, what job you want them to do and the type of person you are looking for. You can then plan the interview and decide on the type of questions you would like to ask. If you don’t have a job description and person specification then it is important to take some time to write one. Its is important for a candidate to make a good impression on you but you also need to make a good impression on them. In the current climate candidates have a lot…
Imagine setting off on a journey. If you don’t know where you are going you will never get there. Before you read a CV for an applicant you need to consider how this role fits into your team, what job you want them to do and the type of person you are looking for. You can then plan the interview and decide on the type of questions you would like to ask. If you don’t have a job description and person specification then it is important to take some time to write one. Its is important for a candidate to make a good impression on you but you also need to make a good impression on them. In the current climate candidates have a lot…
- Dossier admits UK biotech at breaking point.
- Sector can still flourish – but needs major investment.
- Industry calls for new investment partnership with government.
- Creation of two new investment super funds critical to future success.
Leading figures from the UK biotechology sector have presented the government with a dossier which identifies the need for ‘seismic’ change to save and transform the industry. Click here to download the dossier Twenty-two biotech leaders, including prominent biotech chairmen, chief executives, brokers and investors signed the dossier which has had inputs from over 50 different British biotech experts. It was recently sent to the Prime Minister and the Business Secretary, Lord Mandelson. The business leaders have been assessing the industry’s ne…
Leading figures from the UK biotechology sector have presented the government with a dossier which identifies the need for ‘seismic’ change to save and transform the industry. Click here to download the dossier Twenty-two biotech leaders, including prominent biotech chairmen, chief executives, brokers and investors signed the dossier which has had inputs from over 50 different British biotech experts. It was recently sent to the Prime Minister and the Business Secretary, Lord Mandelson. The business leaders have been assessing the industry’s ne…
27-Aug-2010
Paul Hartigan reports from the Financial Times Pharmaceutical Conference: London December 2nd and 3rd 2008
At the Financial Times Pharmaceutical Conference, David Brennan, CEO of AstraZeneca, gave the key note address , and issued what might be seen as a warning for those that see Big Pharma as a counter-cyclical safe-haven for investors, saying that it's true people need healthcare regardless of the economy," the economic recession will be " And the evidence is there that Big Pharma is imbibing some cost cutting medicine, with most of the major players reducing sales and marketing expenses, quite often through cuts in the sales force. But it could also be that the massive spend on DTC advertising (which is legal only in the USA and New Zealand will also see some diminution). According to…
At the Financial Times Pharmaceutical Conference, David Brennan, CEO of AstraZeneca, gave the key note address , and issued what might be seen as a warning for those that see Big Pharma as a counter-cyclical safe-haven for investors, saying that it's true people need healthcare regardless of the economy," the economic recession will be " And the evidence is there that Big Pharma is imbibing some cost cutting medicine, with most of the major players reducing sales and marketing expenses, quite often through cuts in the sales force. But it could also be that the massive spend on DTC advertising (which is legal only in the USA and New Zealand will also see some diminution). According to…
27-Aug-2010
Awards for Innovation, Export Achievement and NHS Partnership held at ERBI's Winter Ball at The Imperial War Museum, Duxford on November 29th 2008.
A project which has the capability to shorten patient waiting lists for CT scans used to detect life-threatening conditions such as brain tumours, has won Hope Enterprises the ERBI Medtech 2008 award for NHS Partnership, sponsored by Health Enterprise East. The team worked closely with NHS staff to capture the data needed for specially customised prediction software. The software demonstrated that a ‘zero wait’ can be achieved and a same day service offered to patients, thereby avoiding the need for a return journey to hospital. The award was presented to Roger Thorpe, Managing Director of Hope Enterprises by Barnaby Perks of ERBI Medtech, an…
A project which has the capability to shorten patient waiting lists for CT scans used to detect life-threatening conditions such as brain tumours, has won Hope Enterprises the ERBI Medtech 2008 award for NHS Partnership, sponsored by Health Enterprise East. The team worked closely with NHS staff to capture the data needed for specially customised prediction software. The software demonstrated that a ‘zero wait’ can be achieved and a same day service offered to patients, thereby avoiding the need for a return journey to hospital. The award was presented to Roger Thorpe, Managing Director of Hope Enterprises by Barnaby Perks of ERBI Medtech, an…
27-Aug-2010
Our eMarketing team at PharmiWeb Solutions often works with pharma brand teams to find new ways to reach healthcare professionals with news of the latest product or initiative. And sometimes, it can be challenging, with all of the pressures and time constraints that the average primary care practice faces.
But surely it must be easier for patients? Well, we thought so too, until we came across this recent news story that may be the start of an alarming trend. According to veritable news source Newsbiscuit.com, Moira Braithwaite, 52, of Dorking, Surrey, UK is celebrating her ninth successive Receptionist of the Month Award after preventing over 35,000 patients getting an appointment within 48 hours during the month of September alone. Click here to find out more. Let us know if you’ve come a…
But surely it must be easier for patients? Well, we thought so too, until we came across this recent news story that may be the start of an alarming trend. According to veritable news source Newsbiscuit.com, Moira Braithwaite, 52, of Dorking, Surrey, UK is celebrating her ninth successive Receptionist of the Month Award after preventing over 35,000 patients getting an appointment within 48 hours during the month of September alone. Click here to find out more. Let us know if you’ve come a…
It takes courage to invest €300 million in a production site during a time of financial turmoil”,pointed out Karl-Ludwig Kley, Executive Board Chairman of the pharmaceutical company Merck Serono, this week.
The company, which is part of Merck KGaA, announced in the midst of the world’s greatest global economic downturn it had just made the biggest single investment in its corporate history. On top of the €1 billion it spends on R&D each year, hundreds of millions of euros are being ploughed into the construction of a state-of-the art facility to produce the company’s current and future biotechnology products. The existing site, where Merck Serono has produced its multiple sclerosis biotech product Rebif since 1999, has already achieved the ISO1401 international standard for environment…
The company, which is part of Merck KGaA, announced in the midst of the world’s greatest global economic downturn it had just made the biggest single investment in its corporate history. On top of the €1 billion it spends on R&D each year, hundreds of millions of euros are being ploughed into the construction of a state-of-the art facility to produce the company’s current and future biotechnology products. The existing site, where Merck Serono has produced its multiple sclerosis biotech product Rebif since 1999, has already achieved the ISO1401 international standard for environment…
27-Aug-2010
White paper from CERAM highlights novel techniques to expose fake medicines and unlicensed manufacturing processes
CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences in the manufacturing processes involved. The author of the white paper, Dr. Justine Bentley, explains how technology is helping to stem the trade in counterfeit drugs. She says "Counterfeit medicines are incredibly dangerous and represent a significant challenge to public health, so…
CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences in the manufacturing processes involved. The author of the white paper, Dr. Justine Bentley, explains how technology is helping to stem the trade in counterfeit drugs. She says "Counterfeit medicines are incredibly dangerous and represent a significant challenge to public health, so…
27-Aug-2010
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value.
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007, this sector contributed seven blockbuster drugs, four of which ranked among the top 20 highest revenue generating pr…
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007, this sector contributed seven blockbuster drugs, four of which ranked among the top 20 highest revenue generating pr…
NHS Direct estimate that one in five UK women over forty years of age suffer from stress incontinence and, whilst it is often caused by childbirth or menopause, it can affect any women at any age.
NHS Direct estimate that one in five UK women over forty years of age suffer from stress incontinence and, whilst it is often caused by childbirth or menopause, it can affect any women at any age. But dealing with the embarrassing symptons is only half the problem; the psychological impact can be devestating. One woman describes how her husband thought she had become agrophobic because she refused to go out anymore, another describes how she put her social life on hold and refused to go on holiday. The inhibiting effect also impacts on personal relationships with many women avoiding physical c…
NHS Direct estimate that one in five UK women over forty years of age suffer from stress incontinence and, whilst it is often caused by childbirth or menopause, it can affect any women at any age. But dealing with the embarrassing symptons is only half the problem; the psychological impact can be devestating. One woman describes how her husband thought she had become agrophobic because she refused to go out anymore, another describes how she put her social life on hold and refused to go on holiday. The inhibiting effect also impacts on personal relationships with many women avoiding physical c…
Procter & Gamble Pharmaceuticals (P&GP) acknowledges the publication of the new Technology Appraisal Guidance (TAG 160, for the primary prevention, and 161 for the secondary prevention, of osteoporotic fragility fractures in post-menopausal women) issued by NICE.
- Final Guidance Issued by NICE Monday 27th October 2008: Procter & Gamble Pharmaceuticals (P&GP) acknowledges the publication of the new Technology Appraisal Guidance (TAG 160, for the primary prevention, and 161 for the secondary prevention, of osteoporotic fragility fractures in post-menopausal women) issued by NICE. Within the scope of this guidance NICE considered alendronate, risedronate, etidronate, strontium ranelate, raloxifene and teriparatide (secondary prevention only). P&GP welcomes the recommendation of…
- Final Guidance Issued by NICE Monday 27th October 2008: Procter & Gamble Pharmaceuticals (P&GP) acknowledges the publication of the new Technology Appraisal Guidance (TAG 160, for the primary prevention, and 161 for the secondary prevention, of osteoporotic fragility fractures in post-menopausal women) issued by NICE. Within the scope of this guidance NICE considered alendronate, risedronate, etidronate, strontium ranelate, raloxifene and teriparatide (secondary prevention only). P&GP welcomes the recommendation of…
27-Aug-2010
The following is taken from the ABPI's Press Release dated 29th October 2008
Top-ups are a prime example of the inequalities that exist within the UK’s healthcare systems. We believe that they are not only discriminatory but also unnecessary. The notion that there is not enough money to pay for new medicines is wrong. Medicines are making up a smaller and smaller part of the overall NHS budget.See Figure 1. (Source:PPA, ONS, DH, NAW, ISD, IMS dataview). In 2007, medicines accounted for just 9.9 per cent of the overall budget. See Figure 2. (Source: OHE compendium) While people in the UK are being denied access to modern medicines that enhance and prolong life, they are readily available in other European countries, where prices and spending are higher. In 2007, the UK spent £195 pe…
Top-ups are a prime example of the inequalities that exist within the UK’s healthcare systems. We believe that they are not only discriminatory but also unnecessary. The notion that there is not enough money to pay for new medicines is wrong. Medicines are making up a smaller and smaller part of the overall NHS budget.See Figure 1. (Source:PPA, ONS, DH, NAW, ISD, IMS dataview). In 2007, medicines accounted for just 9.9 per cent of the overall budget. See Figure 2. (Source: OHE compendium) While people in the UK are being denied access to modern medicines that enhance and prolong life, they are readily available in other European countries, where prices and spending are higher. In 2007, the UK spent £195 pe…
Boehringer Ingelheim and the search for new targeted cancer treatments
Founded in 1885, Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim am Rhein, Germany, it is a family-owned, globally operating research-driven group of companies committed to the goal of serving mankind through research into diseases and the development of new treatment options of high therapeutic value for human and veterinary medicine. The Boehringer Ingelheim group, with 137 subsidiaries in 47 countries across the world and a total of approximately 38,500 employees, reported net sales of almost 10.6 billion Euros in 2006. With its activities focused on Human Pharmaceuticals and Animal Health, Boehringer Ingelheim demonstrates a clear commitment to improving the…
Founded in 1885, Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim am Rhein, Germany, it is a family-owned, globally operating research-driven group of companies committed to the goal of serving mankind through research into diseases and the development of new treatment options of high therapeutic value for human and veterinary medicine. The Boehringer Ingelheim group, with 137 subsidiaries in 47 countries across the world and a total of approximately 38,500 employees, reported net sales of almost 10.6 billion Euros in 2006. With its activities focused on Human Pharmaceuticals and Animal Health, Boehringer Ingelheim demonstrates a clear commitment to improving the…
Dr George Patino (aka Giorgio Giovanni Paticciano), 48 years old and a Mexican citizen by birth, was sentenced today at Kingston Crown Court to 3 years imprisonment.
Dr George Patino (aka Giorgio Giovanni Paticciano), 48 years old and a Mexican citizen by birth, was sentenced today at Kingston Crown Court to 3 years imprisonment. He is the latest in a group of businessmen engaged in a conspiracy to be prosecuted by the Medicines and Healthcare products Regulatory Agency (MHRA) in an operation known as Stormgrand. This operation led to convictions in one of the biggest conspiracies of the supply of counterfeit medicines of its kind in the UK. Over a period of nine months (February 2005 – October 2005) Dr Patino, with the help of his co-conspirator Ashish Halai, bought nearly $237,000 worth…
Dr George Patino (aka Giorgio Giovanni Paticciano), 48 years old and a Mexican citizen by birth, was sentenced today at Kingston Crown Court to 3 years imprisonment. He is the latest in a group of businessmen engaged in a conspiracy to be prosecuted by the Medicines and Healthcare products Regulatory Agency (MHRA) in an operation known as Stormgrand. This operation led to convictions in one of the biggest conspiracies of the supply of counterfeit medicines of its kind in the UK. Over a period of nine months (February 2005 – October 2005) Dr Patino, with the help of his co-conspirator Ashish Halai, bought nearly $237,000 worth…
Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Eli Lilly and Company (NYSE: LLY) announced today that its wholly-owned subsidiary, Alaska Acquisition Corporation, has commenced its tender offer for all outstanding shares of ImClone Systems Incorporated (Nasdaq: IMCL) at a price of $70.00 net per share in cash. Lilly and ImClone previously announced that they had reached a definitive merger agreement for Lilly to acquire ImClone. The Board of Directors of ImClone has unanimously determined that the offer and the merger are fair to, and in the best interests of, ImClone and its shareholders; approved and declared advisable the merger agreement and the transactions contemplated thereby, including the offer; and recommended that holders of shares of ImClone common stock…
Eli Lilly and Company (NYSE: LLY) announced today that its wholly-owned subsidiary, Alaska Acquisition Corporation, has commenced its tender offer for all outstanding shares of ImClone Systems Incorporated (Nasdaq: IMCL) at a price of $70.00 net per share in cash. Lilly and ImClone previously announced that they had reached a definitive merger agreement for Lilly to acquire ImClone. The Board of Directors of ImClone has unanimously determined that the offer and the merger are fair to, and in the best interests of, ImClone and its shareholders; approved and declared advisable the merger agreement and the transactions contemplated thereby, including the offer; and recommended that holders of shares of ImClone common stock…
Data Indicate Bioabsorbable Stent Platform Has Potential to Become the Next Major Breakthrough in Interventional Treatment
Washington — Abbott (NYSE: ABT) today announced two-year data from 30 patients in its ABSORB clinical trial, demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries. Patients who received Abbott's bioabsorbable drug eluting coronary stent and were followed out to two years experienced no stent thrombosis out to two years and no new major adverse cardiac events (MACE) between six months and two years. These results confirmed earlier positive one-year clinical re…
Washington — Abbott (NYSE: ABT) today announced two-year data from 30 patients in its ABSORB clinical trial, demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries. Patients who received Abbott's bioabsorbable drug eluting coronary stent and were followed out to two years experienced no stent thrombosis out to two years and no new major adverse cardiac events (MACE) between six months and two years. These results confirmed earlier positive one-year clinical re…
The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the guts incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when blood sugar is low.
The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the gut’s incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when blood sugar is low. Their action seems to be merely to enhance a natural process. However, given concerns about the impact of other oral antidiabetic drugs on the heart, clinicians and patients are asking what impact, if any, DPP-4 inhibitors have on cardiovascular disease. Over the past couple of years, the link between antidiabetic drugs and heart disease has been a hot topic…
The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the gut’s incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when blood sugar is low. Their action seems to be merely to enhance a natural process. However, given concerns about the impact of other oral antidiabetic drugs on the heart, clinicians and patients are asking what impact, if any, DPP-4 inhibitors have on cardiovascular disease. Over the past couple of years, the link between antidiabetic drugs and heart disease has been a hot topic…
27-Aug-2010
This months feature focus from PharmiWeb.com covers the difference between a common cold and flu, the various symptoms and recent preventions.
The common cold and flu are both contagious viral infections of the respiratory tract. Although the symptoms can be similar, flu is much worse. A cold may drag you down a bit, but the flu can make you shudder at the very thought of getting out of bed. Congestion, sore throat, and sneezing are common with colds. Both cold and flu bring coughing, headache, and chest discomfort. With the flu, though, you are likely to run a high fever for several days and have headache, fatigue, and weakness. Usually, complications from colds are relatively minor, but a severe case of flu can lead to a life-threatening illness such as pneumonia. More than 100 types o…
The common cold and flu are both contagious viral infections of the respiratory tract. Although the symptoms can be similar, flu is much worse. A cold may drag you down a bit, but the flu can make you shudder at the very thought of getting out of bed. Congestion, sore throat, and sneezing are common with colds. Both cold and flu bring coughing, headache, and chest discomfort. With the flu, though, you are likely to run a high fever for several days and have headache, fatigue, and weakness. Usually, complications from colds are relatively minor, but a severe case of flu can lead to a life-threatening illness such as pneumonia. More than 100 types o…
